CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 444 filers reported holding CRISPR THERAPEUTICS AG in Q1 2022. The put-call ratio across all filers is 0.99 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $8,076,470 | +9.2% | 177,935 | +35.1% | 0.02% | +8.7% |
| Q2 2023 | $7,394,256 | +117.9% | 131,711 | +135.9% | 0.02% | +64.3% |
| Q2 2022 | $3,394,000 | -12.4% | 55,840 | -9.5% | 0.01% | +7.7% |
| Q1 2022 | $3,873,000 | +39.8% | 61,690 | +149.2% | 0.01% | +30.0% |
| Q3 2021 | $2,771,000 | +1153.8% | 24,759 | +1264.9% | 0.01% | +900.0% |
| Q1 2021 | $221,000 | -94.2% | 1,814 | -92.7% | 0.00% | -94.1% |
| Q4 2020 | $3,801,000 | +288.3% | 24,826 | +112.1% | 0.02% | +325.0% |
| Q3 2020 | $979,000 | -84.4% | 11,706 | -86.3% | 0.00% | -87.5% |
| Q2 2020 | $6,268,000 | +1347.6% | 85,287 | +735.7% | 0.03% | +966.7% |
| Q1 2020 | $433,000 | -84.7% | 10,206 | -78.0% | 0.00% | -66.7% |
| Q4 2019 | $2,825,000 | +55.2% | 46,394 | -9.0% | 0.01% | +28.6% |
| Q1 2019 | $1,820,000 | +364.3% | 50,959 | +477.7% | 0.01% | +600.0% |
| Q3 2018 | $392,000 | – | 8,821 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $31,294,000 | 31.24% |
| NEA Management Company, LLC | 1,590,002 | $365,593,000 | 10.56% |
| Ariose Capital Management Ltd | 37,900 | $2,379,000 | 9.30% |
| ARK Investment Management | 9,404,071 | $590,294,000 | 2.46% |
| NIA IMPACT ADVISORS, LLC | 80,082 | $5,027,000 | 2.44% |
| Nikko Asset Management Americas, Inc. | 4,619,747 | $291,044,000 | 2.14% |
| PLUSTICK MANAGEMENT LLC | 50,000 | $3,139,000 | 1.98% |
| Integral Health Asset Management, LLC | 120,000 | $7,532,000 | 1.96% |
| Valiant Capital Management, L.P. | 240,683 | $15,108,000 | 1.73% |
| Deuterium Capital Management, LLC | 18,000 | $1,130,000 | 1.45% |